Skip to search formSkip to main contentSkip to account menu

ARRY-334543

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

QuinazolinesThiazolesVarlitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study
ARRY-334543 is an oral, potent, ATP-competitive, selective, reversible inhibitor of ErbB1 (EGFR), ErbB2 (HER2), and ErbB4 (HER4… 
2009
2009
Abstract #1757: In vivo activity of ARRY-334543, a potent, small molecule inhibitor of EGFR/ErbB2 in combination with trastuzumab or docetaxel
ARRY-334543 is an orally active, potent small molecule tyrosine kinase inhibitor targeting both EGFR and ErbB2. The compound is a…